{
    "organizations": [],
    "uuid": "31e0a324f682c895c4338a07869aa5be7f83dc88",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-mirati-therapeutics-reports-q1-los/brief-mirati-therapeutics-reports-q1-loss-per-share-0-51-idUSASC0A06Y",
    "ord_in_thread": 0,
    "title": "Mirati Therapeutics Reports Q1 Loss Per Share $0.51",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 7 (Reuters) - Mirati Therapeutics Inc:\n* MIRATI THERAPEUTICS REPORTS FIRST QUARTER FINANCIAL RESULTS\n* Q1 LOSS PER SHARE $0.51 * Q1 EARNINGS PER SHARE VIEW $-0.60 â€” THOMSON REUTERS I/B/E/S\n* QTRLY TOTAL REVENUE $9.5 MILLION * ON TRACK TO FILE PLANNED INDA FOR MRTX849, A POTENT AND SELECTIVE INHIBITOR FOR KRAS, IN Q4 OF 2018 Source text for Eikon:\nOur ",
    "published": "2018-05-08T04:13:00.000+03:00",
    "crawled": "2018-05-08T16:45:02.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "mirati",
        "therapeutic",
        "inc",
        "mirati",
        "therapeutic",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "qtrly",
        "total",
        "revenue",
        "million",
        "track",
        "file",
        "planned",
        "inda",
        "mrtx849",
        "potent",
        "selective",
        "inhibitor",
        "kras",
        "q4",
        "source",
        "text",
        "eikon"
    ]
}